Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma
Cancer Letters · 2024-02 · 582 · 216593
DOI: 10.1016/j.canlet.2023.216593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-02. Verfasst von Mei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, …. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Acquisition of resistance to temozolomide (TMZ) poses a significant challenge in glioblastoma (GBM) therapy. Neovascularization, a pivotal process in tumorigenesis and development, remains poorly understood in its contribution to chemoresistance in GBMs. This study unveils aberrant vascular networks within TMZ-resistant (TMZ-R) GBM tissues and identifies the extracellular matrix (ECM) protein CCBE1 as a potential mediator. Through in vivo and in vitro experiments involving gain and loss of function assessments, we demonstrate that high expression of CCBE1 promotes hyper-angiogenesis and orchestrates partial endothelial-to-mesenchymal transition (EndMT) in human microvascular endothelial cells (HCMEC/d3) within GBM. This is likely driven by VEGFC/Rho signaling. Intriguingly, CCBE1 overexpression substantially fails to promote tumor growth, but endows resistance to GBM cells in a vascular endothelial cell-dependent manner. Mechanically, the constitutive phosphorylation of SP1 at Ser101 drives the upregulation of CCBE1 transcription in TMZ resistant tumors, and the excretion of CCBE1 depends on caveolae associated protein 1 (CAVIN1) binding and assembling. Tumor cells derived CCBE1 promotes VEGFC maturation, activates VEGFR2/VEGFR3/Rho signaling in vascular endothelial cells, and ultimately results in hyper-angiogenesis in TMZ-R tumors. Collectively, the current study uncovers the cellular and molecular basis of abnormal angiogenesis in a chemo resistant microenvironment, implying that curbing CCBE1 is key to reversing TMZ resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China; Center of Clinical Res…
- Department of Nuclear Medicine, T Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, C…
Zitieren
APA
Wang, M., Xia, D., Xu, D., Yin, Y., Xu, F., Zhang, B., Li, K., Yang, Z., & Zou, J. (2024). Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma. Cancer Letters, 582, 216593. https://doi.org/10.1016/j.canlet.2023.216593
Vancouver
Wang M, Xia D, Xu D, Yin Y, Xu F, Zhang B, et al. Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma. Cancer Letters. 2024;582:216593. doi:10.1016/j.canlet.2023.216593
BibTeX
@article{Wang2024,
author = {Wang, Mei and Xia, Die and Xu, Daxing and Yin, Ying and Xu, Fei and Zhang, Bo and Li, Koukou and Yang, Zhenkun and Zou, Jian},
title = {Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma},
journal = {Cancer Letters},
year = {2024},
volume = {582},
pages = {216593},
doi = {10.1016/j.canlet.2023.216593}
}
EUVIMED